Ravindra Deshpande

About

Self-motivated and goal-oriented cancer biologist/molecular biologist: More than 3 years of experience in preclinical models of oncology.
o Substantial experience in designing and executing well-controlled in-vitro and in-vivo assays for drug discovery.
o Experienced in leading multiple projects.
o Proficient in data handling and analysis of experimental results.
o Collaborative and active team player evident in co-authored research manuscripts.
o Innovative and efficient executor: established a model system to study tumor intrinsic heterogeneity imparting resistance to checkpoint-blockade therapy

Employment

• Wake Forest University School of Medicine Postdoctoral fellow
  2018 - Present

Education

• University of Hyderabad PhD
• University of Hyderabad PhD
• University of Hyderabad PhD

Projects & Funding

Projects & funding information is unavailable.

Publications (30)

• Identification of TUBB3 as an immunotherapy target in lung cancer by genome wide in vivo CRISPR screening
  Neoplasia (United States) 2025 DOI: 10.1016/j.neo.2024.101100
  +Save
• Correction: Regucalcin promotes dormancy of prostate cancer (Oncogene, (2021), 40, 5, (1012-1026), 10.1038/s41388-020-01565-9)
  Oncogene 2024 DOI: 10.1038/s41388-024-03216-9
  +Save
• Functional evaluation of dendritic cells and extracellular vesicles as immunotherapy for breast cancer
  Oncogene 2024 DOI: 10.1038/s41388-023-02893-2
  +Save
• Tumor-intrinsic CDC42BPB confers resistance to anti-PD-1 immune checkpoint blockade in breast cancer
  Molecular Therapy 2024 DOI: 10.1016/j.ymthe.2024.07.021
  +Save
• Editorial: Clinicopathological factors and staging in gastrointestinal cancers
  Frontiers in Oncology 2023 DOI: 10.3389/fonc.2023.1193216
  +Save
• Engineering an active immunotherapy for personalized cancer treatment and prevention of recurrence
  Science Advances 2023 DOI: 10.1126/SCIADV.ADE0625
  +Save
• Long Noncoding RNAs: Emerging Biomarkers of Therapy Resistance and Tumor Progression
  Technology in Cancer Research and Treatment 2023 DOI: 10.1177/15330338221150328
  +Save
• Publisher Correction: Exosomal miR-1304-3p promotes breast cancer progression in African Americans by activating cancer-associated adipocytes (Nature Communications, (2022), 13, 1, (7734), 10.1038/s41467-022-35305-2)
  Nature Communications 2023 DOI: 10.1038/s41467-023-36009-x
  +Save
• Exosomal miR-1304-3p promotes breast cancer progression in African Americans by activating cancer-associated adipocytes
  Nature Communications 2022 DOI: 10.1038/s41467-022-35305-2
  +Save
• Reactive Oxygen Species in Glioma: Mechanisms and Challenges
  Handbook of Oxidative Stress in Cancer: Therapeutic Aspects: Volume 1 2022 DOI: 10.1007/978-981-16-5422-0_145
  +Save